Why Investors Are Voting Against Novo Nordisk

In this video, health-care analyst David Williamson discusses the day's three biggest losers in the sector, including Novo Nordisk, which dropped more than 8% in advance of its FDA advisory committee meeting for long-acting insulin Tresiba on Thursday. Watch and find out why investors are feeling glum after reading the FDA's briefing documents and catch up on the day's other big movers.

And since today is Election Day, check out our free report: "These Could Skyrocket After the 2012 Presidential Election." Barack Obama and Mitt Romney have competing visions for getting America back on track, but The Motley Fool will have you prepared to profit -- no matter who wins! Download your copy now, for free, and discover hidden ways to profit from the election.

The article Why Investors Are Voting Against Novo Nordisk originally appeared on Fool.com.

Brenton Flynn, David Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.